文献速递类风湿关节炎

阿巴西普应答与类风湿关节炎患者T细胞蛋白酶体β1i表达抑制相关

Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2020-01-01

该研究在39例类风湿关节炎(RA)患者中观察阿巴西普治疗24周对蛋白酶体的影响,发现持续应答者CD4+和CD8+ T细胞中免疫蛋白酶体亚单位β1i显著降低,且阿巴西普未影响蛋白酶体糜蛋白酶样活性或凋亡诱导。

要点

  • 阿巴西普治疗16周55%、24周70%患者达缓解或低疾病活动度。
  • 仅持续应答者CD4+和CD8+ T细胞中β1i在16周和24周显著降低。
  • 阿巴西普不影响蛋白酶体糜蛋白酶样活性及体外凋亡诱导。

核心结论

  • RA患者对阿巴西普持续应答与T细胞免疫蛋白酶体亚单位β1i表达降低相关,提示T细胞免疫蛋白酶体与RA疾病活动相关。

研究设计与样本

  • 研究纳入39例RA患者,观察阿巴西普治疗24周,采用实时PCR检测分选血细胞中组成型和免疫蛋白酶体催化亚单位转录水平,并评估蛋白酶体活性和凋亡诱导。

主要发现

  • 阿巴西普在16周时55%患者达缓解或低疾病活动度,24周时70%患者达缓解或低疾病活动度。
  • 双因素方差分析显示,仅持续应答者CD4+和CD8+ T细胞中蛋白酶体免疫亚单位β1i在16周和24周均显著降低。
  • 单因素方差分析确认上述结果,并显示同一组CD4+和CD8+ T细胞在24周显著降低。
  • 阿巴西普不影响蛋白酶体糜蛋白酶样活性,且体外暴露于蛋白酶体抑制剂时对凋亡诱导无影响。

临床怎么用

  • 阿巴西普治疗RA时,T细胞β1i表达降低可能与持续临床应答相关,可作为潜在生物标志物进一步研究。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Abatacept is a biological disease-modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (RA) and modulates the costimulatory signal by cluster of differentiation (CD)28:CD80/CD86 interaction required for T cell activation. Since CD28-mediated signalling regulates many T cell functions including cytokine production of, for example, interferons (IFNs), it is of interest to clarify, whether response to abatacept has an effect on the IFN inducible immunoproteasome, as a central regulator of the immune response. METHODS: Effects of abatacept on the proteasome were investigated in 39 patients with RA over a period of 24 weeks. Using real-time PCR, transcript levels of constitutive and corresponding immunoproteasome catalytic subunits were investigated at baseline (T0), week 16 (T16) and week 24 (T24) in sorted blood cells. Proteasomal activity and induction of apoptosis after proteasome inhibition were also evaluated. RESULTS: Abatacept achieved remission or low disease activity in 55% of patients at T16 and in 70% of patients at T24. By two-way analysis of variance (ANOVA), a significant reduction of proteasome immunosubunit β1i was shown only in CD4+ and CD8+ T cells of sustained responders at both T16 and T24. One-way ANOVA analysis for each response group confirmed the results and showed a significant reduction at T24 in CD4+ and CD8+ T cells of the same group. Abatacept did not influence chymotrypsin-like activity of proteasome and had no effect on induction of apoptosis under exposure to a proteasome inhibitor in vitro. CONCLUSION: The reduction of proteasome immunosubunit β1i in T cells of patients with RA with sustained response to abatacept suggests association of the immunoproteasome of T cells with RA disease activity.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ghannam K, Martinez Gamboa L, Kedor C, et al. Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis. RMD Open. 2020. PMID: 32998980. doi:10.1136/rmdopen-2020-001248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。